Both FGFR1- and FGF2-expressing EGFR+cells showed an EMT phenotype and upregulate FGF9 in FGFR1-expressing ALK+cells exhibiting characteristics of SCLC, and such features underly the acquired DTP state along with resistance to targeted TKIs6,29–32. The gene discussed is FGF2; the disease is small cell lung carcinoma.